Disease · EFO_0009856
lichen planopilaris
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. lichen planopilaris. Diseases, record EFO_0009856. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009856
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- lichen planopilaris
- Open Targets ID
- EFO_0009856
- Other names
- Follicular lichen planus, Frontal fibrosing alopecia (subtype), Kossard disease, LPP, Lichen follicularis, Lichen planopilaris classic type, Lichen planus follicularis
- Highest stage of its drugs
- Phase 2/3, for 1 of its 12 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BREPOCITINIB | CHEMBL4297477 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DELGOCITINIB | CHEMBL4297507 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEUCRAVACITINIB | CHEMBL4435170 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MECHLORETHAMINE | CHEMBL427 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NALTREXONE | CHEMBL19019 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| UPADACITINIB | CHEMBL3622821 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IXEKIZUMAB | CHEMBL1743034 | Antibody | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HYDROXYCHLOROQUINE | CHEMBL1535 | Small molecule | Unknown | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Unknown | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CYCLOSPORINE | CHEMBL160 | Protein | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets15
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| TYK2 | Janus Kinase (JAK) | 5 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator | Phase 2/3 | https://conductscience.org/library/genes/7297 | Drugs and targets |
| JAK1 | Janus Kinase (JAK) | 4 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor | Phase 2 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| JAK3 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor | Phase 2 | https://conductscience.org/library/genes/3718 | Drugs and targets |
| DHFR | Dihydrofolate reductase | 1 | Dihydrofolate reductase inhibitor | Unknown | https://conductscience.org/library/genes/1719 | Drugs and targets |
| IL17A | Interleukin-17A | 1 | Interleukin 17A inhibitor | Early phase 1 | https://conductscience.org/library/genes/3605 | Drugs and targets |
| OPRD1 | Opioid receptors; mu/kappa/delta | 1 | Opioid receptors; mu/kappa/delta antagonist | Phase 2 | https://conductscience.org/library/genes/4985 | Drugs and targets |
| OPRK1 | Opioid receptors; mu/kappa/delta | 1 | Opioid receptors; mu/kappa/delta antagonist | Phase 2 | https://conductscience.org/library/genes/4986 | Drugs and targets |
| OPRM1 | Opioid receptors; mu/kappa/delta | 1 | Opioid receptors; mu/kappa/delta antagonist | Phase 2 | https://conductscience.org/library/genes/4988 | Drugs and targets |
| PPIA | Peptidyl-prolyl cis-trans isomerase A | 1 | Cyclophilin A modulator | Unknown | https://conductscience.org/library/genes/5478 | Drugs and targets |
1 to 10 of 15
See all 15 targetsTrials10
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04409041 | Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia | Phase 2 | 43 | 2021-12-30 | Lichen Planopilaris, Frontal Fibrosing Alopecia | NALTREXONE | Its record names the disease | ClinicalTrials.gov |
| NCT03417141 | Valchlor in the Treatment of Lichen Planopilaris | Phase 2 | 12 | 2020-07-02 | Lichen Planopilaris | MECHLORETHAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT06091956 | A Study of Deucravacitinib to Treat LPP and FFA | Phase 2 | 12 | 2025-06-08 | Lichen Planopilaris | DEUCRAVACITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT06202560 | Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study | Not applicable | 11 | 2025-05-30 | Frontal Fibrosing Alopecia, Lichen Planopilaris of Scalp | TOFACITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT07532603 | A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris | Phase 2/3 | 342 | Lichen Planopilaris | BREPOCITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT06512766 | a Retrospective Study on the Systemic Treatment of LPP and FFA | 315 | Cicatricial Alopecia, Lichen Planopilaris, Lichen Plano-Pilaris, Frontal Fibrosing Alopecia, Hair Diseases, Scarring Alopecia, Hair Loss/Baldness | CYCLOSPORINE, HYDROXYCHLOROQUINE, METHOTREXATE | Its record names the disease | ClinicalTrials.gov | ||
| NCT06512753 | The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Lichen Planopilaris in Routine Clinical Care: a Patient Preference Trial | 56 | Lichen Planopilaris, Cicatricial Alopecia | HYDROXYCHLOROQUINE, METHOTREXATE | Its record names the disease | ClinicalTrials.gov | ||
| NCT07492251 | Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study. | Phase 2 | 56 | Lichen Penis Planus | UPADACITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT07487948 | Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris | Phase 2 | 30 | Central Centrifugal Cicatricial Alopecia, Lichen Planopilaris | DELGOCITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT05030415 | Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris | Early phase 1 | 9 | Lichen Planus Scalp, Lichen Planus, Lichen Planopilaris | IXEKIZUMAB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials0
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
None in this release.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0009856
GET https://conductscience.org/api/diseases/v1/EFO_0009856/drugs